Liver News and Research

RSS

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

15 Jul 2009

Focusing HIV treatment helps control concurrent hepatitis B infection

Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications, according to a new study by researchers at Wake Forest University School of Medicine.

15 Jul 2009

Ethicists urge inclusion of pregnant women in Federal child-health study

A team of ethicists from Johns Hopkins, Duke and Georgetown universities is urging organizers of a recently begun $3 billion decades-long study of children's health to immediately add provisions to look at the health and medical profiles of the children's mothers during their pregnancies.

9 Jul 2009

Costliest Medicare markets in Florida, New York, California

U.S. News & World Report examines cost, frequency, and outcomes studies on Medicare patients from the Dartmouth Institute for Health Policy and Clinical Practice : "The Dartmouth research is particularly relevant to older Americans because it is based to a large extent on Medicare data, involving patients ages 65 and older.

8 Jul 2009

NDA for Exenatide once weekly accepted for FDA review

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).

7 Jul 2009

Warnings about ‘over-use’ of paracetamol

A panel of experts in the United States has raised new concerns about the popular painkiller paracetamol and are calling for the Food and Drug Administration (FDA) to reduce the maximum dose of paracetamol allowed because they say 'over-use' can cause serious liver damage.

5 Jul 2009

Discovery of new gene associated with diabetes

Research led by the German Institute of Human Nutrition (DIfE) has identified a new gene associated with diabetes, together with a mechanism that makes obese mice less susceptible to diabetes.

5 Jul 2009

Report card on UK's health

Medical scientists from Southampton have contributed to a major new report, setting out plans to enhance the nation's health by improving diet, increasing physical activity and cutting harmful drinking.

2 Jul 2009

Newly discovered gene regulates balance of 'bad' cholesterol

In an article in Science, Noam Zelcer from the LACDR describes a previously unknown mechanism for regulating the amount of LDL cholesterol. This offers opportunities for supplementing and improving the effect of so-called statins: medicines that remove 'bad' cholesterol from the bloodstream.

30 Jun 2009

Breast milk ingredient protects babies' intestines

Scientists at Queen Mary, University of London have discovered that an ingredient in human breast milk protects and repairs the delicate intestines of newborn babies.

30 Jun 2009

Sometimes insurance no match for health costs

Americans with serious illnesses who must often choose between paying a mortgage or their health premiums and deductibles are often going broke, The Seattle Times reports.

30 Jun 2009

Rise in alcohol deaths worldwide down to women drinkers

Canadian researchers have found that as many as 1 in 25 deaths worldwide can be attributed to alcohol and this rise since 2000 is mainly due to increases in the number of women drinking.

28 Jun 2009

Expanding quantum dot utility in cancer diagnosis and treatment

Quantum dots (QDs), nanoparticles that shine with extraordinary brightness when excited by light energy, have shown promise as new tools for detecting cancer at its earliest appearance, but concerns about potential toxicities have limited their clinical development. Researchers at the University of Buffalo may have found an answer to this limitation with their development of a new way to create QDs.

28 Jun 2009

Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy

An interdisciplinary team of researchers at Brigham and Women's Hospital and the Harvard-Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology has demonstrated a better way to deliver cancer drugs directly to tumors.

28 Jun 2009

Early detection of pancreatic cancer closer thanks to multifunctional nanoparticles

Pancreatic cancer has a devastatingly low survival rate (less than 5 percent after 5 years) because it is usually diagnosed at an advanced stage. The initial symptoms, such as pain, jaundice, or weight loss, often do not allow the disease to be caught early enough for surgery and chemotherapy to be effective.

28 Jun 2009

Computer-guided nanoparticle therapy destroys tumors

Gold nanoshells are among the most promising new nanoscale therapeutics being developed to kill tumors, acting as antennas that turn light energy into heat that cooks cancer to death. Now, a multi-institutional research team has shown that polymer-coated gold nanorods one-up their spherical counterparts, with a single dose completely destroying all tumors in a nonhuman animal model of human cancer.

28 Jun 2009

Artificial liver for drug tests

If you have hay fever, headaches or a cold, it's only a short way to the nearest chemist. The drugs, on the other hand, can take eight to ten years to develop.

25 Jun 2009

Discovery of potent metastasis inhibitor

Researchers at Children's Hospital Boston have isolated a potent inhibitor of tumor metastasis made by tumor cells, one that could potentially be harnessed as a cancer treatment.

23 Jun 2009

Research shows how obesity sets the stage for diabetes

Obesity is probably the most important factor in the development of insulin resistance, but science's understanding of the chain of events is still spotty. Now, researchers at the Salk Institute for Biological Studies have filled in the gap and identified the missing link between the two.

22 Jun 2009

Targeting tumor behavior may find new anti-cancer agents

Ohio State University cancer researchers have used computational and genomic methods to identify possible anti-cancer agents that may block a particular kind of tumor behavior. The agents target multiple genes associated with that behavior at one time.

18 Jun 2009